Jared Silver

521 total citations
38 papers, 299 citations indexed

About

Jared Silver is a scholar working on Physiology, Surgery and Immunology and Allergy. According to data from OpenAlex, Jared Silver has authored 38 papers receiving a total of 299 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Physiology, 15 papers in Surgery and 15 papers in Immunology and Allergy. Recurrent topics in Jared Silver's work include Asthma and respiratory diseases (17 papers), Allergic Rhinitis and Sensitization (15 papers) and Eosinophilic Esophagitis (11 papers). Jared Silver is often cited by papers focused on Asthma and respiratory diseases (17 papers), Allergic Rhinitis and Sensitization (15 papers) and Eosinophilic Esophagitis (11 papers). Jared Silver collaborates with scholars based in United States, United Kingdom and Canada. Jared Silver's co-authors include Peter Howarth, John Oppenheimer, Wanda Phipatanakul, Njira Lugogo, Flavia Hoyte, Beth Hahn, Michael Bogart, Elizabeth Packnett, Matthew Warren and Glen E. Duncan and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, CHEST Journal and Journal of Allergy and Clinical Immunology.

In The Last Decade

Jared Silver

29 papers receiving 298 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jared Silver United States 9 216 104 96 68 53 38 299
Amani El-Gammal Canada 8 270 1.3× 89 0.9× 100 1.0× 9 0.1× 140 2.6× 8 433
S Kubo Japan 11 170 0.8× 210 2.0× 39 0.4× 8 0.1× 53 1.0× 22 344
Latifa Khalfaoui United States 7 279 1.3× 92 0.9× 163 1.7× 16 0.2× 41 0.8× 16 356
Charles H. Banov United States 10 218 1.0× 175 1.7× 124 1.3× 17 0.3× 18 0.3× 16 322
Marta Bartezaghi Italy 8 86 0.4× 36 0.3× 60 0.6× 11 0.2× 10 0.2× 19 204
David Proud United States 10 288 1.3× 214 2.1× 136 1.4× 15 0.2× 30 0.6× 13 443
M. L. Kowalski Poland 4 61 0.3× 44 0.4× 32 0.3× 31 0.5× 23 0.4× 6 151
A. Chartier France 11 161 0.7× 170 1.6× 52 0.5× 5 0.1× 59 1.1× 33 303
E Martí-Guadaño Spain 9 308 1.4× 290 2.8× 106 1.1× 9 0.1× 16 0.3× 9 388
J.L. Rodriguez-Bada Spain 7 170 0.8× 250 2.4× 33 0.3× 8 0.1× 8 0.2× 18 339

Countries citing papers authored by Jared Silver

Since Specialization
Citations

This map shows the geographic impact of Jared Silver's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jared Silver with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jared Silver more than expected).

Fields of papers citing papers by Jared Silver

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jared Silver. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jared Silver. The network helps show where Jared Silver may publish in the future.

Co-authorship network of co-authors of Jared Silver

This figure shows the co-authorship network connecting the top 25 collaborators of Jared Silver. A scholar is included among the top collaborators of Jared Silver based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jared Silver. Jared Silver is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pongdee, Thanai, et al.. (2025). Mepolizumab Reduces Systemic Corticosteroid (SCS)-Related Toxicities Compared to Chronic SCS Use in Patients with EGPA. Journal of Allergy and Clinical Immunology. 155(2). AB455–AB455.
2.
Pfaar, Oliver, Anju T. Peters, Camille Taillé, et al.. (2025). Chronic rhinosinusitis with nasal polyps: Key considerations in the multidisciplinary team approach. Clinical and Translational Allergy. 15(1). e70010–e70010. 3 indexed citations
3.
4.
Silver, Jared, et al.. (2025). Enhancing Rural Healthcare Accessibility: A Model for Pharmacogenomics Adoption via an Outreach-Focused Integration Strategy. Journal of Personalized Medicine. 15(3). 110–110.
5.
Wechsler, Michael E., Anna Kovalszki, Jared Silver, et al.. (2025). Eosinophilic granulomatosis with polyangiitis: Patient profiles from a large US allergy practice. Journal of Allergy and Clinical Immunology Global. 4(2). 100437–100437.
6.
7.
8.
9.
Bernstein, Jonathan A., Jared Silver, Elizabeth Packnett, et al.. (2024). Real-world unified airway benefits of mepolizumab. Annals of Allergy Asthma & Immunology. 133(4). 422–429.e2. 1 indexed citations
10.
Silver, Jared, Elizabeth Packnett, Julie Park, & Arijita Deb. (2023). Biologic use and treatment patterns in patients with chronic rhinosinusitis with nasal polyps: a US real-world study. Allergy Asthma and Clinical Immunology. 19(1). 104–104. 3 indexed citations
11.
Desrosiers, Martin, Zuzana Diamant, Paolo Castelnuovo, et al.. (2023). Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24‐week treatment‐free follow‐up. International Forum of Allergy & Rhinology. 14(1). 18–31. 19 indexed citations
12.
Silver, Jared, et al.. (2023). Real‐world effectiveness of mepolizumab in severe asthma and chronic rhinosinusitis in the United States: Impact of comorbidity and sinus surgery. International Forum of Allergy & Rhinology. 14(1). 5–17. 4 indexed citations
13.
Bachert, Claus, Amber Luong, Philippe Gevaert, et al.. (2023). The Unified Airway Hypothesis: Evidence From Specific Intervention With Anti–IL-5 Biologic Therapy. The Journal of Allergy and Clinical Immunology In Practice. 11(9). 2630–2641. 20 indexed citations
14.
Borish, Larry, Noah Cohen, Geoffrey Chupp, et al.. (2022). Evaluating enrollment and outcome criteria in trials of biologics for chronic rhinosinusitis with nasal polyps. Annals of Allergy Asthma & Immunology. 129(2). 160–168. 17 indexed citations
15.
Oppenheimer, John, Flavia Hoyte, Wanda Phipatanakul, et al.. (2022). Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions. Annals of Allergy Asthma & Immunology. 129(2). 169–180. 66 indexed citations
16.
Bhattacharyya, Neil, Jared Silver, Michael Bogart, et al.. (2022). Profiling Disease and Economic Burden in CRSwNP Using Machine Learning. Journal of Asthma and Allergy. Volume 15. 1401–1412. 3 indexed citations
17.
Silver, Jared, Michael Bogart, Néstor A. Molfino, et al.. (2021). Factors leading to discontinuation of biologic therapy in patients with severe asthma. Journal of Asthma. 59(9). 1839–1849. 14 indexed citations
18.
Silver, Jared, Néstor A. Molfino, Michael Bogart, et al.. (2021). Real-world impact of mepolizumab in patients with life-threatening asthma: US insurance claims database analysis. Clinical Therapeutics. 43(12). 2064–2073. 6 indexed citations
19.
Casale, Thomas B., Néstor A. Molfino, Jared Silver, et al.. (2021). Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities. Annals of Allergy Asthma & Immunology. 127(3). 354–362.e2. 26 indexed citations
20.
Silver, Jared, Michael Bogart, Elizabeth Packnett, et al.. (2020). <p>Real-World Reductions in Oral Corticosteroid Use in the USA Following Mepolizumab Therapy for Severe Asthma</p>. Journal of Asthma and Allergy. Volume 13. 689–699. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Amani El-Gammal Breakdown of academic impact, for papers by S Kubo Breakdown of academic impact, for papers by Latifa Khalfaoui Breakdown of academic impact, for papers by Charles H. Banov Breakdown of academic impact, for papers by Marta Bartezaghi Breakdown of academic impact, for papers by David Proud Breakdown of academic impact, for papers by M. L. Kowalski Breakdown of academic impact, for papers by A. Chartier Breakdown of academic impact, for papers by E Martí-Guadaño Breakdown of academic impact, for papers by J.L. Rodriguez-Bada
Rankless by CCL
2026